Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704764 | 0.83 | IDO1 (0.48) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL564873 | 0.82 | SLC6A2 (0.36) | IDO1AGXTRIPK1SMN1; SMN2SLC6A2 | |
| SCHEMBL564609 | 0.81 | NPC1 (0.43) | SMN1; SMN2ALDH1A1SLC6A2HTR2AHTR2B | |
| SCHEMBL33527402 | 0.81 | NR3C1 (0.36) | IDO1AGXTRIPK1SLC6A2TAAR1 | |
| SCHEMBL20746123 | 0.81 | IDO1 (0.47) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL3799579 | 0.81 | HTR2A (0.50) | IDO1ALDH1A1SLC6A2TAAR1HTR2A | |
| SCHEMBL30090103 | 0.80 | RIPK1 (0.46) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL564882 | 0.80 | RIPK1 (0.46) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 | |
| SCHEMBL24160334 | 0.79 | SLC6A2 (0.40) | RIPK1SMN1; SMN2SLC6A2TAAR1TRPA1 | |
| SCHEMBL13548281 | 0.78 | RIPK1 (0.49) | IDO1AGXTRIPK1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562603-B3 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-1765355-B1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7727984-B2 | R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1562603-B1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-2025338-A1 | New medicaments for the treatment of chronic ostructive pulmonary disease | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-7056916-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050277632-A1 | Beta agonists for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| WO-2005110990-A1 | HYDROXY-SUBSTITUTED BENZO-CONDENSED HETEROCYCLES FOR USE AS BETA AGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005102350-A1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | IDO1 2974/4885AGXT 3258/4885RIPK1 4864/4885 |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IDO1 3165/4885AGXT 2130/4885RIPK1 4815/4885 |
| US-20050277632-A1 | Beta agonists for the treatment of respiratory diseases | ADRB1, ADRB2, ADRA1B | IDO1 2478/4885AGXT 3165/4885RIPK1 4777/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | IDO1 2893/4885AGXT 958/4885RIPK1 4814/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | IDO1 2838/4885AGXT 1887/4885RIPK1 4830/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | IDO1 2893/4885AGXT 958/4885RIPK1 4814/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | IDO1 1760/4885AGXT 2295/4885RIPK1 4721/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | IDO1 2797/4885AGXT 1275/4885RIPK1 4392/4885 |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | ADRB1, ADRB2, ADRB3 | IDO1 2974/4885AGXT 3258/4885RIPK1 4864/4885 |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | CHRM1, CHRM2, ADRA2C | IDO1 594/4885AGXT 2440/4885RIPK1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.